Emergent Biosolutions (EBS) Expected to Announce Earnings on Monday

Emergent Biosolutions (NYSE:EBS) is projected to announce its Q4 2025 results after the market closes on Monday, March 2nd. Analysts expect Emergent Biosolutions to post earnings of $0.11 per share and revenue of $217.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Emergent Biosolutions Stock Performance

Shares of EBS opened at $10.95 on Monday. The firm has a market cap of $574.83 million, a price-to-earnings ratio of 8.42 and a beta of 2.35. The company’s fifty day moving average is $11.86 and its 200-day moving average is $10.35. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. Emergent Biosolutions has a 12 month low of $4.02 and a 12 month high of $14.06.

Analyst Ratings Changes

Several research firms have commented on EBS. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Wall Street Zen upgraded Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.00.

Insider Activity

In other news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the transaction, the director directly owned 98,417 shares in the company, valued at approximately $1,178,051.49. The trade was a 18.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Emergent Biosolutions by 10.2% during the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock worth $33,327,000 after buying an additional 250,616 shares during the last quarter. Millennium Management LLC raised its stake in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Emergent Biosolutions by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,252,605 shares of the biopharmaceutical company’s stock valued at $27,841,000 after purchasing an additional 112,265 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Emergent Biosolutions by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock valued at $20,010,000 after purchasing an additional 237,153 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Emergent Biosolutions by 14.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,132,305 shares of the biopharmaceutical company’s stock worth $9,987,000 after purchasing an additional 145,632 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.